Ribeiro JE, Castro LB, Silva MA, Lima MB; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 790 (abstract no. 41240).
University of Rio de Janeiro, Brasil.
OBJECTIVES: Compare the results obtaind on the treatment of HIV patients (PT) using antiretroviral combined therapy (ACT) only with the results of other PT using subcutaneous recombinant Interleukin-2 (rIL-2) associated with ACT. The influence of rIL-2 over the CD4 cells and collateral effects, toxity levels and therapy efficiency. DESIGN: Prospective, controlled study. METHODS: A total of 36 PT infected by HIV, under ambulatorial care, ages from 20 to 55 years, both male and female, with a number of at least 200 CD4 cells/mm3, using ACT for more than 6 months and with a viral load under 1000 conts of RNA of HIV (PCR method), were observed. No acute infections were observed at that moment. Those PT were separeted in 2 groups: Group 1--PT using only ACT (control group) and Group 2--PT using ACT that hav also received rIL-2 (PROLEUKIN), subcutaneously, in doses of 18 MIU/day on a 5-day cycle, every 8 weeks in 3 cycles. Every PT was checked, before and after each cycle, on immunologic, virologic an bioquimical basis. RESULTS: Group 1 presented a mean of 378 CD4 cells/mm3 on the beginning of the study, and 399 in the end. In group 2, a initial mean of 349 and 686 CD4 cell/mm3 in the and, without toxity levels. CONCLUSION: This study shows that the use of rIL-2 associated with ACT proportionates a significant increase of the number of CD4 cells/mm3 (a mean of 98.3%), reinstating, therefore, the immunologic system, keeping the viral load low.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- CD4-Positive T-Lymphocytes
- Drug Therapy, Combination
- Female
- HIV
- HIV Core Protein p24
- HIV Infections
- HIV Seropositivity
- Humans
- Interleukin-2
- Longitudinal Studies
- Male
- Prospective Studies
- Receptors, Interleukin-2
- Recombinant Proteins
- Viral Load
- aldesleukin
- drug therapy
- immunology
- therapy
Other ID:
UI: 102230888
From Meeting Abstracts